

# Ian R Rifkin

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3676145/ian-r-rifkin-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

49  
papers

5,048  
citations

28  
h-index

53  
g-index

53  
ext. papers

5,508  
ext. citations

8.7  
avg, IF

4.98  
L-index

#	Paper	IF	Citations
49	Novel ELISA Protocol Links Pre-Existing SARS-CoV-2 Reactive Antibodies With Endemic Coronavirus Immunity and Age and Reveals Improved Serologic Identification of Acute COVID-19 Multi-Parameter Detection. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 614676	8.4	4
48	Monoallelic IRF5 deficiency in B cells prevents murine lupus. <i>JCI Insight</i> , <b>2021</b> , 6,	9.9	1
47	Inhibition of IRF4 in dendritic cells by PRR-independent and -dependent signals inhibit Th2 and promote Th17 responses. <i>ELife</i> , <b>2020</b> , 9,	8.9	9
46	c-Cbl targets PD-1 in immune cells for proteasomal degradation and modulates colorectal tumor growth. <i>Scientific Reports</i> , <b>2019</b> , 9, 20257	4.9	16
45	Follicular Dendritic Cell Activation by TLR Ligands Promotes Autoreactive B Cell Responses. <i>Immunity</i> , <b>2017</b> , 46, 106-119	32.3	60
44	TLR sensing of bacterial spore-associated RNA triggers host immune responses with detrimental effects. <i>Journal of Experimental Medicine</i> , <b>2017</b> , 214, 1297-1311	16.6	15
43	Inhibition of type 4 cyclic nucleotide phosphodiesterase blocks intracellular TLR signaling in chronic lymphocytic leukemia and normal hematopoietic cells. <i>Journal of Immunology</i> , <b>2015</b> , 194, 101-12	5.3	11
42	Promotion of Inflammatory Arthritis by Interferon Regulatory Factor 5 in a Mouse Model. <i>Arthritis and Rheumatology</i> , <b>2015</b> , 67, 3146-57	9.5	28
41	IRF5 deficiency ameliorates lupus but promotes atherosclerosis and metabolic dysfunction in a mouse model of lupus-associated atherosclerosis. <i>Journal of Immunology</i> , <b>2015</b> , 194, 1467-79	5.3	45
40	The immunomodulatory parasitic worm product ES-62 reduces lupus-associated accelerated atherosclerosis in a mouse model. <i>International Journal for Parasitology</i> , <b>2015</b> , 45, 203-7	4.3	32
39	CpGB DNA activates dermal macrophages and specifically recruits inflammatory monocytes into the skin. <i>Experimental Dermatology</i> , <b>2015</b> , 24, 133-9	4	5
38	Peroxisome proliferator-activated receptor gamma agonists in the prevention and treatment of murine systemic lupus erythematosus. <i>Immunology</i> , <b>2014</b> , 142, 363-73	7.8	19
37	Interferon regulatory factor-5 deficiency ameliorates disease severity in the MRL/lpr mouse model of lupus in the absence of a mutation in DOCK2. <i>PLoS ONE</i> , <b>2014</b> , 9, e103478	3.7	20
36	Gene expression during the generation and activation of mouse neutrophils: implication of novel functional and regulatory pathways. <i>PLoS ONE</i> , <b>2014</b> , 9, e108553	3.7	55
35	Evaluating the role of nucleic acid antigens in murine models of systemic lupus erythematosus. <i>Methods in Molecular Biology</i> , <b>2014</b> , 1169, 143-58	1.4	2
34	Phenotype and function of B cells and dendritic cells from interferon regulatory factor 5-deficient mice with and without a mutation in DOCK2. <i>International Immunology</i> , <b>2013</b> , 25, 295-306	4.9	39
33	The effect of mycophenolate mofetil on disease development in the gld.apoE (-/-) mouse model of accelerated atherosclerosis and systemic lupus erythematosus. <i>PLoS ONE</i> , <b>2013</b> , 8, e61042	3.7	17

32	PDE4 Inhibitors Block TLR7 and TLR9-Driven Signaling, Proliferation and Cytokine Secretion in CLL Cells As Well As Proliferation Driven by Exposure to Apoptotic Cells. <i>Blood</i> , <b>2012</b> , 120, 1774-1774	2.2	
31	Role for toll-like receptors in autoimmune disease: the example of systemic lupus erythematosus. <i>Joint Bone Spine</i> , <b>2011</b> , 78, 124-30	2.9	73
30	Implication des Toll-like récepteurs dans les maladies auto-immunes : exemple du lupus érythémateux systémique. <i>Revue Du Rhumatisme (Edition Francaise)</i> , <b>2011</b> , 78, 18-25	0.1	
29	Poly(I:C) drives type I IFN- and TGFβ-mediated inflammation and dermal fibrosis simulating altered gene expression in systemic sclerosis. <i>Journal of Investigative Dermatology</i> , <b>2010</b> , 130, 2583-93	4.3	104
28	IFN regulatory factor 5 is required for disease development in the FcγRIIB <sup>-/-</sup> and FcγRIIB <sup>-/-</sup> mouse models of systemic lupus erythematosus. <i>Journal of Immunology</i> , <b>2010</b> , 184, 796-806	5.3	75
27	Role for interferon regulatory factors in autoimmunity. <i>Joint Bone Spine</i> , <b>2010</b> , 77, 525-31	2.9	18
26	Implication de la famille des facteurs de transcription IRF dans l'auto-immunité. <i>Revue Du Rhumatisme (Edition Francaise)</i> , <b>2010</b> , 77, 556-562	0.1	
25	Murine B cell response to TLR7 ligands depends on an IFN-beta feedback loop. <i>Journal of Immunology</i> , <b>2009</b> , 183, 1569-76	5.3	93
24	Requirement for DNA CpG content in TLR9-dependent dendritic cell activation induced by DNA-containing immune complexes. <i>Journal of Immunology</i> , <b>2009</b> , 183, 3109-17	5.3	94
23	TLR4 ligands induce IFN-alpha production by mouse conventional dendritic cells and human monocytes after IFN-beta priming. <i>Journal of Immunology</i> , <b>2009</b> , 182, 820-8	5.3	41
22	The peroxisome proliferator-activated receptor gamma agonist rosiglitazone ameliorates murine lupus by induction of adiponectin. <i>Journal of Immunology</i> , <b>2009</b> , 182, 340-6	5.3	75
21	DNA-like class R inhibitory oligonucleotides (INH-ODNs) preferentially block autoantigen-induced B-cell and dendritic cell activation in vitro and autoantibody production in lupus-prone MRL-Fas(lpr/lpr) mice in vivo. <i>Arthritis Research and Therapy</i> , <b>2009</b> , 11, R79	5.7	44
20	Murine dendritic cell type I IFN production induced by human IgG-RNA immune complexes is IFN regulatory factor (IRF)5 and IRF7 dependent and is required for IL-6 production. <i>Journal of Immunology</i> , <b>2007</b> , 178, 6876-85	5.3	145
19	Immunologically active autoantigens: the role of toll-like receptors in the development of chronic inflammatory disease. <i>Annual Review of Immunology</i> , <b>2007</b> , 25, 419-41	34.7	317
18	A 57-year-old woman with recently diagnosed SLE, proteinuria, and microhematuria. <i>American Journal of Kidney Diseases</i> , <b>2006</b> , 48, 1004-8	7.4	2
17	DNA and RNA autoantigens as adjuvants. <i>Journal of Endotoxin Research</i> , <b>2006</b> , 12, 379-84		15
16	B cells and dendritic cells from V kappa 8 light chain transgenic mice activate MRL-lpr/gld CD4 <sup>+</sup> T cells. <i>Journal of Immunology</i> , <b>2006</b> , 177, 45-52	5.3	1
15	Simvastatin treatment ameliorates autoimmune disease associated with accelerated atherosclerosis in a murine lupus model. <i>Journal of Immunology</i> , <b>2006</b> , 177, 3028-34	5.3	80

14	Lupus nephritis. <i>Seminars in Nephrology</i> , <b>2006</b> , 26, 95-104	4.8	19
13	Toll-like receptors, endogenous ligands, and systemic autoimmune disease. <i>Immunological Reviews</i> , <b>2005</b> , 204, 27-42	11.3	337
12	RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. <i>Journal of Experimental Medicine</i> , <b>2005</b> , 202, 1171-7	16.6	649
11	Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. <i>Journal of Experimental Medicine</i> , <b>2004</b> , 199, 1631-40	16.6	434
10	Impaired clearance of apoptotic cells promotes synergy between atherogenesis and autoimmune disease. <i>Journal of Experimental Medicine</i> , <b>2004</b> , 199, 1121-31	16.6	143
9	Comparison of CpG s-ODNs, chromatin immune complexes, and dsDNA fragment immune complexes in the TLR9-dependent activation of rheumatoid factor B cells. <i>Journal of Endotoxin Research</i> , <b>2004</b> , 10, 247-51		31
8	The stimulation of Toll-like receptors by nuclear antigens: a link between apoptosis and autoimmunity. <i>Rheumatic Disease Clinics of North America</i> , <b>2004</b> , 30, 559-74, ix	2.4	22
7	Toll-like receptors and activation of autoreactive B cells. <i>Current Directions in Autoimmunity</i> , <b>2003</b> , 6, 105-22		45
6	Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. <i>Nature</i> , <b>2002</b> , 416, 603-7	50.4	1583
5	Immune complexes present in the sera of autoimmune mice activate rheumatoid factor B cells. <i>Journal of Immunology</i> , <b>2000</b> , 165, 1626-33	5.3	66
4	Kinetics and functional implications of Th1 and Th2 cytokine production following activation of peripheral blood mononuclear cells in primary culture. <i>European Journal of Immunology</i> , <b>1996</b> , 26, 1260-5	6.1	62
3	Successful control of hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis using magnesium carbonate and calcium carbonate as phosphate binders. <i>Nephron</i> , <b>1993</b> , 63, 379-83	3.3	30
2	SARS-CoV-2 reactive antibodies in unexposed individuals revealed by a high sensitivity, low noise serologic assay		5
1	Distinct Autoimmune Antibody Signatures Between Hospitalized Acute COVID-19 Patients, SARS-CoV-2 Convalescent Individuals, and Unexposed Pre-Pandemic Controls		14